Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

,

In Partnership With:

OncLive News Network® | <b>Treatment Updates in Ph+ Acute Lymphoblastic Leukemia</b>

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.